| Literature DB >> 33041974 |
Yue-Bei Luo1, Yuyao Peng1, Yuling Lu2, Qiuxiang Li1, Huiqian Duan1, Fangfang Bi1, Huan Yang1.
Abstract
Background: Myofibrillar myopathy is a group of hereditary neuromuscular disorders characterized by dissolution of myofibrils and abnormal intracellular accumulation of Z disc-related proteins. We aimed to characterize the clinical, physiological, pathohistological, and genetic features of Chinese myofibrillar myopathy patients from a single neuromuscular center.Entities:
Keywords: BAG3opathy; FHL1opathy; desminopathy; filaminopathy; myofibrillar myopathy; titinopathy
Year: 2020 PMID: 33041974 PMCID: PMC7522348 DOI: 10.3389/fneur.2020.01014
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Genetics of the present MFM patient cohort.
| 1 | 2 | 7 | NM_1927 | c.1256C>T | p.Pro419Leu | None | |
| 2 | 2 | 7 | NM_1927 | c.1256C>T | p.Pro419Leu | None | |
| 3 | 2 | 7 | NM_1927 | c.1256C>T | p.Pro419Leu | None | |
| 4 | 2 | 7 | NM_1927 | c.1256C>T | p.Pro419Leu | None | |
| 5 | 2 | 6 | NM_1927 | c.1096_1098delACA | p.Asn366del | ( | |
| 6 | 2 | 6 | NM_1927 | c.1096_1098delACA | p.Asn366del | ( | |
| 7 | 2 | 6 | NM_1927 | c.1096_1098delACA | p.Asn366del | ( | |
| 8 | 2 | 6 | NM_1927 | c.1076_1077ins | p.Glu359delins | None | |
| 9 | 10 | 3 | NM_004281 | c.626C>T | p.Pro209Leu | ( | |
| 10 | 10 | 3 | NM_004281 | c.626C>T | p.Pro209Leu | ( | |
| 11 | 7 | 36 | NM_001458 | c.6004+3G>A | splicing | None | |
| 12 | 7 | 33 | NM_001458 | c.5468C>T | P.Thr1823Met | None | |
| 13 | X | 5 | NM_001159702 | c.386G>A | p.Cys129Tyr | None | |
| 14 | 2 | 344 | NM_001267550 | c.95134T>C | p.Cys31712Arg | ( | |
| 15 | 2 | 344 | NM_001267550 | c.95185T>C | p.Trp31729Arg | ( | |
| 16 | 2 | 69 | NM_001267550 | c. 19993G>T | p.Glu6665X | None | |
| 363 | NM_001267550 | c. 107545delG | p.Ala35849Glnfs*16 | None | |||
| 17 | 2 | 69 | NM_001267550 | c. 19993G>T | p.Glu6665X | None | |
| 363 | NM_001267550 | c. 107545delG | p.Ala35849Glnfs*16 | None | |||
| 18 | None | - | - | - | - | - | - |
Clinical features of the present MFM patient cohort.
| 1 | M | 37 | 5 | Lower proximal | – | 747 | PI/right heart + LA enlargement |
| 2 | M | 33 | 8 | Upper + lower proximal + distal | – | 935.7 | PI/LA enlargement |
| 3 | M | 33 | 3 | Lower distal | – | 1366 | Frequent APB + CRBBB + LAFB/LA enlargement |
| 4 | F | 45 | 8 | Upper + lower proximal + distal | – | 383.4 | NA |
| 5 | M | 42 | 1 | Lower distal | – | 227.7 | CRBBB |
| 6 | M | 30 | 6 | Lower proximal | – | 1568.2 | CRBBB/LA enlargement |
| 7 | M | 48 | 19 | Upper + lower proximal + distal | – | 75.3 | PI |
| 8 | M | 13 | 20 | Upper + lower proximal + distal | – | 1016.5 | Normal |
| 9 | F | 5 | 20 | Lower distal | Achilles tendon/rigid spine | 374.2 | Obstructive hypertrophic cardiomyopathy |
| 10 | F | 9 | 10 | Lower proximal + distal; scapular winging | Achilles tendon/talipes cavus/scoliosis | 1269.7 | Mild mitral + tricuspid + pulmonary valve regurgitation |
| 11 | M | 37 | 10 | Upper distal | MCP/PIP/elbow/scoliosis | 691.3 | NA |
| 12 | F | 35 | 6 | Lower proximal | – | 259.2 | Normal |
| 13 | F | 6 | 2 | Lower proximal + distal | – | 450.8 | Mild mitral + tricuspid regurgitation |
| 14 | M | 42 | 10 | Upper + lower distal | – | 302.1 | LAFB/LA enlargement |
| 15 | M | 15 | 5 | Upper + lower proximal + distal | Achilles tendon/scoliosis | 340.5 | Atrial septal defect-closed |
| 16 | F | 1 | 27 | Lower proximal + distal | Talipes cavus/scoliosis | 375.1 | Mild mitral + tricuspid + pulmonary valve regurgitation |
| 17 | F | 1 | 26 | Lower proximal + distal | Talipes cavus/scoliosis | 296 | Normal |
| 18 | M | 18 | 5 | Lower proximal | – | 993.2 | Mild mitral + tricuspid regurgitation |
CRBBB, complete right bundle branch block; LA, left atrium; LAFB, left anterior fascicular block; NA, not available; PI, pacemaker implant.
Electromyographic features of the present MFM patient cohort.
| 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| 2 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 3 | ✓ | ✓ | |||||||
| 4 | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| 5 | ✓ | ✓ | ✓ | ||||||
| 6 | ✓ | ✓ | |||||||
| 7 | ✓ | ||||||||
| 8 | ✓ | ||||||||
| 9 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| 10 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| 11 | ✓ | ✓ | ✓ | ||||||
| 12 | ✓ | ✓ | ✓ | ✓ | |||||
| 13 | ✓ | ✓ | ✓ | ✓ | |||||
| 14 | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| 15 | ✓ | ||||||||
| 16 | ✓ | ||||||||
| 17 | ✓ | ✓ | ✓ | ||||||
| 18 | ✓ | ✓ | ✓ | ||||||
Myopathological changes of the present MFM patient cohort.
| 1 | 0.9 | 0.5 | 15.0 | 6.6 | 0.5 | 16.0 | 0.2 | 0.1 | 5.6 | 12.8 | 9.2 | 14.1 | + |
| 2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 3 | 2.9 | 2.1 | 22.2 | 3.1 | 2.5 | 3.8 | 11.5 | 3.5 | 6.5 | 19.7 | 3.8 | 3.3 | ++ |
| 4 | 1.1 | 0.9 | 9.5 | 1.5 | 0.4 | 4.9 | 2.5 | 1.5 | 6.8 | 5.5 | 1.8 | 1.5 | – |
| 5 | 0.1 | 0.4 | 38.4 | 6.0 | 0.6 | 5.1 | 0.4 | 0.0 | 5.3 | 9.0 | 3.6 | 3.4 | + |
| 6 | 0.2 | 0.3 | 11.1 | 2.2 | 1.1 | 4.1 | 0.2 | 0.0 | 2.3 | 3.7 | 3.1 | 4.6 | + |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| 8 | 0.6 | 0.0 | 3.4 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 1.0 | 0.1 | 0.2 | ++ |
| 9 | 0.3 | 0.1 | 1.0 | 0.5 | 6.7 | 6.8 | 0.0 | 0.0 | 0.8 | 6.4 | 5.7 | 6.5 | – |
| 10 | 0.4 | 0.0 | 1.8 | 2.4 | 1.4 | 2.2 | 0.4 | 0.0 | 2.0 | 4.3 | 3.6 | 2.3 | ++ |
| 11 | 0.6 | 0.4 | 12.4 | 0.0 | 0.0 | 0.0 | 0.4 | 1.8 | 0.0 | 0.0 | 0.0 | 0.0 | ++ |
| 12 | 0.3 | 0.2 | 18.5 | 0.0 | 0.0 | 0.0 | 0.9 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | – |
| 13 | 0.1 | 0.0 | 10.0 | 2.4 | 4.4 | 1.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.5 | + |
| 14 | 1.3 | 0.9 | 31.4 | 1.1 | 4.5 | 0.0 | 0.2 | 0.0 | 1.4 | 5.0 | 1.8 | 3.9 | + |
| 15 | 0.0 | 0.2 | 10.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.8 | 0.3 | 0.0 | + |
| 16 | 0.5 | 1.1 | 86.8 | 0.1 | 0.3 | 0.3 | 2.6 | 4.0 | 0.9 | 4.3 | 1.8 | 0.0 | + |
| 17 | 1.3 | 0.6 | 79.3 | 0.4 | 0.6 | 11.9 | 2.9 | 0.3 | 0.0 | 8.8 | 1.5 | 0.8 | + |
| 18 | 2.7 | 0.7 | 36.7 | 1.8 | 0.0 | 2.0 | 2.0 | 0.0 | 0.7 | 1.5 | 1.1 | 1.3 | ++ |
−, no interstitial proliferation; +, ++ corresponds to mild, moderate interstitial proliferation.
Figure 1Pedigree charts of the enrolled MFM patients. (A–D) illustrate the three desminopathy families. (E) demonstrates the family tree of patients 16 and 17. For panel (E), gray bar represents the c. 107545delG mutation carrier, black bar the c. 19993G>T carrier.
Figure 2(A) HE staining shows the numerous intramuscular eosinophilic deposits in BAG3opathy (arrow, patient 9); (B–D) immunohistochemistry of serial sections from patient 9 shows aggregation of MFM-related proteins [(B), desmin; (C), BAG3; (D), αB crystallin; different field from (A)], eosinophilic aggregates were most strongly immunoreactive with BAG3 in this patient. Note the aggregates concentrated at the upper myofascicle, while the lower right fascicle appeared normal. (E) HE staining shows fiber size variation and rare regeneration in filaminopathy (patient 11). (F) HE demonstrates eosinophilic materials in FHL1opathy (arrow, patient 13). Note the overall small fiber size. (G) HE shows vacuolated fibers (arrow), central nucleated fibers, and nuclear clumps in HMERF (patient 15). (H) Gomori shows fibers with necklace cytoplasmic bodies (arrow, patient 14). (I,J) HE and NADH demonstrates increased central nuclei and selective type 1 atrophy in titinopathy (patient 16). (K) HE shows rimmed vacuoles (arrow) and esosinophilic bodies (arrowhead) in titinopathy (patient 17). (L) NADH shows relative preservation of the myofibrillar network in the majority of fibers except for occasional bar-like enzyme aggregation (arrow) in patient 17. Magnification: ×200.
Figure 3Comparison of the FLNC intronic c.6004+3 nucleotide among different species. *indicates the conserved nucleotide.